Celgene International Sárl (CELG) Release: Results of Pivotal Study (MCL-001) Evaluating REVLIMID in Mantle-Cell Lymphoma Presented at 54th American Society of Hematology Annual Meeting  
12/11/2012 10:21:46 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced results from the “EMERGE” study (MCL-001), a phase II, multi-center, single-arm trial evaluating REVLIMID® (lenalidomide) in patients with previously treated mantle cell lymphoma (MCL).